Abstract:You have accessJournal of UrologyCME1 May 2022MP06-09 SINGLE CELL ANALYSES OF MURINE UROTHELIAL CARCINOMA CELLS REVEAL A ROLE OF TUMOR-ASSOCIATED MACROPHAGES IN RESPONSE TO ANTI-PD1 THERAPY Dongbo Xu, Li Wang, Yali Zhang, Yanqing Wang, Xiaojing Zhang, Yue Wu, Gary Smith, Bo Xu, Prashant Singh, Yuesheng Zhang, David Goodrich, Jianmin Wang, and Qiang Li Dongbo XuDongbo Xu More articles by this author , Li WangLi Wang More articles by this author , Yali ZhangYali Zhang More articles by this author , Yanqing WangYanqing Wang More articles by this author , Xiaojing ZhangXiaojing Zhang More articles by this author , Yue WuYue Wu More articles by this author , Gary SmithGary Smith More articles by this author , Bo XuBo Xu More articles by this author , Prashant SinghPrashant Singh More articles by this author , Yuesheng ZhangYuesheng Zhang More articles by this author , David GoodrichDavid Goodrich More articles by this author , Jianmin WangJianmin Wang More articles by this author , and Qiang LiQiang Li More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002523.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Approximately 80% of patients with advanced bladder cancer do not respond to immune checkpoint inhibitor (ICI) immunotherapy. The molecular mechanism of ICI treatment response remains unknown largely due to the lack of clinically relevant immunocompetent mouse models. METHODS: We developed a syngeneic triple knockout (TKO: Trp53/Pten/Rb1) bladder cancer model in immunocompetent C57 BL/6J mice. Mouse urothelial cells (Trp53f/f, Ptenf/f, Rb1f/f) were transfected ex vivo with Ad5CMVCre (Adenovirus Cre recombinase driven by a CMV promoter). The TKO urothelial cells were subcutaneously injected into immunocompetent C57 BL/6J for tumor formation. The tumors were treated with an anti-PD1 antibody (BioXcell, RMP1-14, 200 μg, intraperitoneally twice weekly) (n=9) or a control IgG (n=9). Single cell analyses were performed for tumor xenografts from control IgG (n=2), responders (30% less than the median of control tumors) (n=2) and non-responders (n=2) using PTPRC (also named CD45) expression as an immune cell marker. Seurat package was used for data analysis including dimension reduction, cell clustering, and identification of cell markers. SingleR package was utilized to identify the cell types. Immunohistochemistry (IHC) of CD8 and F4/80 was performed to identify T cells and macrophages respectively. RESULTS: Anti-PD-1 immunotherapy resulted in a mixed pattern of treatment responses in individual tumors. Eight clusters of immune cells were identified (basophils, B cells, dendritic cells, macrophages, monocytes, neutrophils, NK cell, and T cells) in ICI treated xenografts. Responder xenografts displayed significantly increased immune cell infiltration (15.2%, 742 immune cells/4861 total cells) compared to the non-responder tumors (10.1%, 452 immune cells/4459 total cells, Fisher Exact Test p<0.0001). Specifically, there were more T cells (46/4861 vs 18/4459, p=0.002), and macrophages (420/4861 vs 287/4459, p=0.002) in responder xenografts than in non-responder xenografts. Compared to control IgG tumors, a near complete response tumor exhibited an immune-inflamed phenotype with significant infiltration of T cells and macrophages, whereas non-responder tumors showed no significant change of T cells and macrophages infiltration. CONCLUSIONS: The higher percentage of T cells and macrophages tumor infiltration in responders suggests a potential role of innate immune microenvironment for the ICI treatment response. Modulating tumor associated macrophage may overcome the resistance to ICI immunotherapy. Source of Funding: This research work was supported in part by NIH Grants, K08CA252161(Li, Q), P30CA016056 (NCI Cancer Center Core Support Grant), the Roswell Park Alliance Foundation and the Friends of Urology Foundation © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e80 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dongbo Xu More articles by this author Li Wang More articles by this author Yali Zhang More articles by this author Yanqing Wang More articles by this author Xiaojing Zhang More articles by this author Yue Wu More articles by this author Gary Smith More articles by this author Bo Xu More articles by this author Prashant Singh More articles by this author Yuesheng Zhang More articles by this author David Goodrich More articles by this author Jianmin Wang More articles by this author Qiang Li More articles by this author Expand All Advertisement PDF DownloadLoading ...

PD59-12 MICROWAVE ABLATION COMBINED WITH ANTI-PD-1/CTLA-4 THERAPY INDUCES ANTI-TUMOR IMMUNE RESPONSE TO RENAL CELL CARCINOMA IN A MURINE MODEL

Microwave Ablation Combined with Anti-Pd-1/ctla-4 Therapy Induces Anti-Tumor Immune Response to Renal Cell Carcinoma in a Murine Model

Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model

MP06-09 SINGLE CELL ANALYSES OF MURINE UROTHELIAL CARCINOMA CELLS REVEAL A ROLE OF TUMOR-ASSOCIATED MACROPHAGES IN RESPONSE TO ANTI-PD1 THERAPY

Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6

Enhanced Antitumor Efficacy Through Microwave Ablation in Combination with Immune Checkpoints Blockade in Breast Cancer: A Pre-Clinical Study in a Murine Model.

Us-Guided Percutaneous Microwave Ablation of Renal Cell Carcinoma: Intermediate-Term Results

Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy

Initial clinical study of ultrasound guided percutaneous microwave ablation treatment for kidney tumors at T1a stage

Microwave ablation combined with PD‐L1 blockade synergistically promotes Cxcl9‐mediated antitumor immunity

PD61-02 FEASIBILITY AND ONCOLOGIC OUTCOMES OF MICROWAVE ABLATION WITH RENAL TUMORS: A RETROSPECTIVE STUDY OF INTERMEDIATE-TERM FOLLOW-UP RESULTS

Ultrasound guided percutaneous microwave ablation treatment for renal carcinomas at T1a stage: the safety evaluation in clinical application

Ultrasound-guided Percutaneous Microwave Ablation of Bilateral Renal Cell Carcinomas: Focus Upon Safety and Efficacy.

Inducing the Abscopal Effect in Liver Cancer Treatment: The Impact of Microwave Ablation Power Levels and PD-1 Antibody Therapy

Microwave Ablation Combined with Flt3L Provokes Tumor‐Specific Memory CD8+ T Cells‐Mediated Antitumor Immunity in Response to PD‐1 Blockade

MP14-18 NEOADJUVANT COMBINATION OF PAZOPANIB OR AXITINIB AND PD-1-ACTIVATED DC-CIK CELLS IMMUNOTHERAPY MAY FACILITATE SURGERY IN PATIENTS WITH RENAL CELL CARCINOMA

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer

Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer

The Effect of Microwave Ablation Combined with Anti-PD-1 Monoclonal Antibody on T Cell Subsets and Long-Term Prognosis in Patients Suffering from Non-Small-Cell Lung Cancer

MP10-03 ANALYSES OF TUMOR MICROENVIRONMENT CHANGES OF CLEAR CELL RENAL CELL CARCINOMA WITH INFERIOR VENA CAVA THROMBUS FOLLOWING NEOADJUVANT ANTI-PD-1 AND TYROSINE KINASE INHIBITOR COMBINATION THERAPY

More Ultrasound-Guided Percutaneous Microwave Ablation Leads to Higher Immune-Related Gene Expression and Boosts PD-1 Monoclonal Antibodies for Liver Cancer